ArticleDiabetology & metabolic syndrome2022
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Samuel J P Malkin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this paperpooled itcites it